Recently, the star product "Fuzheng Huayu Tablets" from Shanghai Huanghai Pharmaceutical Co., Ltd., a subsidiary of Shanghai Baheal Pharma Co., Ltd., has officially received a product license from Canada’s Natural and Non-Prescription Health Products Directorate (NNHPD) under Health Canada. This achievement underscores the company’s breakthrough in the inheritance and innovation of traditional Chinese medicine (TCM) and is poised to accelerate the global expansion of Fuzheng Huayu.

Originating from the 1950s TCM formula "Tao Hong Yin," Fuzheng Huayu has been widely used in China and Southeast Asia for over two decades. Recognized as a leading brand for reversing hepatic fibrosis, it has benefited numerous liver disease patients and is endorsed by mainstream domestic clinical guidelines/consensus. The tablets leverage the advantages of a multi-target compound formulation to protect the liver and combat hepatic fibrosis. Through ongoing pharmacological research and expanded clinical evidence, Fuzheng Huayu Tablets became the first TCM product in the liver disease field to complete Phase II clinical trials in the U.S., pioneering a "dual-therapy" approach that combines antiviral and anti-fibrotic treatments. The product has been honored with prestigious awards, including the "National Science and Technology Progress Second Prize" and the "China Outstanding Patent Award."

As a modern TCM R&D and production base under Baheal Pharma, Huanghai Pharmaceutical adheres to the principles of "diagnosable diseases, controllable quality, and verifiable efficacy" in developing innovative TCM products. The company has introduced advanced formulations such as Fuzheng Huayu and Qishe Pills, addressing unmet needs in challenging disease areas. In production, Huanghai operates a digitized manufacturing facility compliant with FDA quality control standards, ensuring international quality across the entire TCM supply chain to guarantee drug safety and efficacy.

Looking ahead, Baheal Pharma will continue to uphold its mission of "Global Quality, Maintain your Health," collaborating closely with national research institutions to advance the development of high-end formulations, modernized TCM, and original natural medicine products. The company is committed to creating more innovative, China-originated medicines with independent intellectual property rights to optimize clinical outcomes. Simultaneously, it will intensify efforts to promote premium TCM products globally, delivering world-class healthcare solutions to consumers worldwide and contributing to human health.